{
    "id": 1393,
    "fullName": "ALK R1275Q",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ALK R1275Q lies within the protein kinase domain of the Alk protein (UniProt.org). R1275Q confers a gain of function to the Alk protein as demonstrated by transformation activity in cell culture and increased downstream signalling in in vitro assays (PMID: 21838707, PMID: 29533785).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 527,
                    "pubMedId": 21838707,
                    "title": "Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21838707"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 238,
        "geneSymbol": "ALK",
        "terms": [
            "ALK",
            "CD246",
            "NBLST3"
        ]
    },
    "variant": "R1275Q",
    "createDate": "08/12/2014",
    "updateDate": "09/06/2018",
    "referenceTranscriptCoordinates": {
        "id": 102084,
        "transcript": "NM_004304",
        "gDna": "chr2:g.29209798C>T",
        "cDna": "c.3824G>A",
        "protein": "p.R1275Q",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14244,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited proliferation of neuroblastoma cells harboring ALK R1275Q in culture (PMID: 29907598).",
            "molecularProfile": {
                "id": 1416,
                "profileName": "ALK R1275Q"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 11556,
                    "pubMedId": 29907598,
                    "title": "Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29907598"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8371,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing ALK R1275Q in culture, and only delayed tumor growth in cell line xenograft models (PMID: 26554404).",
            "molecularProfile": {
                "id": 1416,
                "profileName": "ALK R1275Q"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6636,
                    "pubMedId": 26554404,
                    "title": "The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26554404"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14241,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited proliferation of neuroblastoma cells harboring ALK R1275Q in culture (PMID: 29907598).",
            "molecularProfile": {
                "id": 1416,
                "profileName": "ALK R1275Q"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11556,
                    "pubMedId": 29907598,
                    "title": "Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29907598"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8376,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorbrena (lorlatinib) inhibited Alk phosphorylation, resulted in growth inhibition of neuroblastoma cells over expressing ALK R1275Q in culture and irapid and sustained complete tumor regression in cell line xenograft models (PMID: 26554404).",
            "molecularProfile": {
                "id": 1416,
                "profileName": "ALK R1275Q"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6636,
                    "pubMedId": 26554404,
                    "title": "The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26554404"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5876,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed cell line expressing ALK R1275Q was sensitive to Alunbrig (brigatinib) in culture and in cell line xenograft models, resulting in cell growth inhibition (PMID: 27049722).",
            "molecularProfile": {
                "id": 1416,
                "profileName": "ALK R1275Q"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5182,
                    "pubMedId": 27049722,
                    "title": "Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27049722"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4730,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to sustain tumor regression in human neuroblastoma cell line xenograft models harboring ALK R1275Q and wild-type TP53 (PMID: 26438783).",
            "molecularProfile": {
                "id": 1416,
                "profileName": "ALK R1275Q"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12798,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CEP-28122 inhibited growth of neuroblastoma cells harboring ALK R1275Q in culture (PMID: 22203728).",
            "molecularProfile": {
                "id": 1416,
                "profileName": "ALK R1275Q"
            },
            "therapy": {
                "id": 2519,
                "therapyName": "CEP-28122",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2441,
                    "pubMedId": 22203728,
                    "title": "CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22203728"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8382,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorlatinib (PF-06463922) inhibited foci formation more efficiently than Xalkori (crizotinib) in transformed cells over expressing ALK R1275Q in culture (PMID: 26554404).",
            "molecularProfile": {
                "id": 1416,
                "profileName": "ALK R1275Q"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6636,
                    "pubMedId": 26554404,
                    "title": "The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26554404"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9667,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of BGB-324 to Xalkori (crizotinib) treatment increased Xalkori (crizotinib)-induced apoptosis in an AXL-expressing neuroblastoma cell line harboring ALK R1275Q in culture, and improved efficacy in xenograft models (PMID: 25450694).",
            "molecularProfile": {
                "id": 26949,
                "profileName": "ALK R1275Q AXL pos"
            },
            "therapy": {
                "id": 5123,
                "therapyName": "BGB-324 + Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7382,
                    "pubMedId": 25450694,
                    "title": "Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25450694"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9666,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of BGB-324 to treatment with Zykadia (ceritinib) increased Zykadia (ceritinib)-induced apoptosis in an AXL-expressing neuroblastoma cell line harboring ALK R1275Q in culture (PMID: 25450694).",
            "molecularProfile": {
                "id": 26949,
                "profileName": "ALK R1275Q AXL pos"
            },
            "therapy": {
                "id": 5124,
                "therapyName": "BGB-324 + Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7382,
                    "pubMedId": 25450694,
                    "title": "Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25450694"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15502,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) restored sensitivity to Lorbrena (lorlatinib) in neuroblastoma cells harboring ALK R1275Q and an acquired NF1 G2392* mutation in culture (PMID: 30322862).",
            "molecularProfile": {
                "id": 31076,
                "profileName": "ALK R1275Q NF1 G2392*"
            },
            "therapy": {
                "id": 7655,
                "therapyName": "Lorlatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13404,
                    "pubMedId": 30322862,
                    "title": "Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322862"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15501,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NF1 G2392* was identified as a potential resistance mutation in a neuroblastoma cell line harboring ALK R1275Q that acquired resistance to Lorbrena (lorlatinib) in culture (PMID: 30322862).",
            "molecularProfile": {
                "id": 31076,
                "profileName": "ALK R1275Q NF1 G2392*"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13404,
                    "pubMedId": 30322862,
                    "title": "Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322862"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1416,
            "profileName": "ALK R1275Q",
            "profileTreatmentApproaches": [
                {
                    "id": 50,
                    "name": "ALK Inhibitor",
                    "profileName": "ALK R1275Q"
                }
            ]
        },
        {
            "id": 18878,
            "profileName": "ALK R1275Q TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26949,
            "profileName": "ALK R1275Q AXL pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31076,
            "profileName": "ALK R1275Q NF1 G2392*",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 102084,
            "transcript": "NM_004304",
            "gDna": "chr2:g.29209798C>T",
            "cDna": "c.3824G>A",
            "protein": "p.R1275Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}